<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623142</url>
  </required_header>
  <id_info>
    <org_study_id>R0047</org_study_id>
    <secondary_id>04/Q1104/26</secondary_id>
    <nct_id>NCT00623142</nct_id>
  </id_info>
  <brief_title>The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery</brief_title>
  <official_title>The Effects of Hyperbaric Oxygen Preconditioning On Cardiovascular Protection &amp; Ischemic Reperfusion Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull and East Yorkshire Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North of England Medical &amp; Hyperbaric Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hull and East Yorkshire Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine if treating patients who have coronary heart
      disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery
      reduces injury to the heart and vascular system during and after surgery. Furthermore, this
      study also aims to identify some of the post CABG clinical effects of HBO treatment prior to
      CABG.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Hsp72 protein</measure>
    <time_frame>Intra-operative (During CABG)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial eNOS protein</measure>
    <time_frame>Intra-Operative (During CABG)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Troponin-T</measure>
    <time_frame>Peri-operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum soluble ICAM-1</measure>
    <time_frame>Peri-operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum soluble PSGL-1</measure>
    <time_frame>Peri-operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum soluble P-Selectin</measure>
    <time_frame>Peri-operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum soluble E-Selectin</measure>
    <time_frame>Peri-operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cardiovascular haemodynamic parameters as measured by a pulmonary artery catheter</measure>
    <time_frame>Peri-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Post Operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of endotracheal intubation</measure>
    <time_frame>post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>Post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotrope usage</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low cardiac output status</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary complications</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Complications</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular complications</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complications</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of ICU stay</measure>
    <time_frame>Post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Myocardial Reperfusion Injury</condition>
  <condition>Cytoprotection</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm were not treated with HBO prior to CABG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm were treated with HBO prior to CABG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric Oxygen</intervention_name>
    <description>100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Hyperbaric Oxygen Preconditioning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective first time CABG

          -  Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG

        Exclusion Criteria:

          -  Age ≤ 20 years or ≥ 85 years

          -  Ejection fraction &lt; 30%

          -  Unstable angina

          -  Recent myocardial infarction (&lt; 1 month)

          -  Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease,
             dissection or elevated pulmonary artery pressure)

          -  Any end stage organ failure (e.g. renal and respiratory failure)

          -  History of chronic obstructive pulmonary disease (COPD)

          -  Pneumothorax

          -  Pulmonary bullae

          -  Convulsions

          -  Current history of malignancy

          -  Severe myopia or intraocular lens

          -  Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid
             Analgesics, Catecholamines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeysen Z Yogaratnam, MB.BCh, BAO, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hull &amp; East Yorkshire NHS Trust (Castle Hill Hospital), United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hull &amp; East Yorkshire NHS Trust (Castle Hill Hospital)</name>
      <address>
        <city>Hull</city>
        <state>East Riding of Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Yogaratnam JZ, Laden G, Guvendik L, Cowen M, Cale A, Griffin S. Pharmacological preconditioning with hyperbaric oxygen: can this therapy attenuate myocardial ischemic reperfusion injury and induce myocardial protection via nitric oxide? J Surg Res. 2008 Sep;149(1):155-64. Epub 2007 Oct 11. Review.</citation>
    <PMID>17996900</PMID>
  </reference>
  <reference>
    <citation>Yogaratnam JZ, Laden G, Guvendik L, Cowen M, Cale A, Griffin S. Can hyperbaric oxygen be used as adjunctive heart failure therapy through the induction of endogenous heat shock proteins? Adv Ther. 2007 Jan-Feb;24(1):106-18. Review.</citation>
    <PMID>17526467</PMID>
  </reference>
  <reference>
    <citation>Yogaratnam JZ, Laden G, Madden LA, Seymour AM, Guvendik L, Cowen M, Greenman J, Cale A, Griffin S. Hyperbaric oxygen: a new drug in myocardial revascularization and protection? Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):146-54. Review.</citation>
    <PMID>16945821</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>February 22, 2008</last_update_submitted>
  <last_update_submitted_qc>February 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jeysen Zivan Yogaratnam</name_title>
    <organization>Hull &amp; East Yorkshire NHS Trust</organization>
  </responsible_party>
  <keyword>Myocardial protection</keyword>
  <keyword>Ischemic Reperfusion Injury</keyword>
  <keyword>Hyperbaric Oxygen</keyword>
  <keyword>Preconditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

